Kevin Janes, Ph.D.

University of Virginia Cancer Center researchers have developed a new way to identify high-risk patients with acute myeloid leukemia, which could one day lead to more tailored treatments and improved patient outcomes for patients with the blood cancer.

Acute myeloid leukemia (AML) is one of the most common leukemias, or blood cancers, in adults. It starts in the blood-forming cells in the bone marrow and often spreads to the bloodstream. Until now, doctors have relied on analyzing patients’ genes and chromosomes to determine who may be at highest risk, but the limitations of that approach have made researchers eager to develop better ways to “stratify” patients and tailor treatments to their needs… Continue reading.

WASHINGTON, D.C. — The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Kevin Janes, Ph.D., Professor, Biomedical Engineering, University of Virginia, to its College of Fellows.

Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers. College membership honors those who have made outstanding contributions to “engineering and medicine research, practice, or education” and to “the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering, or developing/implementing innovative approaches to bioengineering education.”

Dr. Janes was nominated, reviewed, and elected by peers and members of the College of Fellows for “outstanding contributions in data-driven systems biology.“